Research summary
The 2021 ESC guidelines for diagnosis and treatment of acute and chronic heart failure provided updated evidence-based recommendations developed under ESC procedures for guideline development [1]. The ARISTOTLE trial randomized 18,201 atrial fibrillation patients with at least one additional stroke risk factor to apixaban 5 mg twice daily or warfarin (INR target 2.0-3.0), powered for noninferiority on stroke or systemic embolism [2]. The 2012 European cardiovascular disease prevention guidelines, developed by the Fifth Joint Task Force with the European Association for Cardiovascular Prevention & Rehabilitation, integrated cross-society recommendations for clinical practice [3]. The PARADIGM-HF trial randomized 8,442 NYHA class II-IV heart-failure patients with ejection fraction <=40% to LCZ696 (sacubitril/valsartan) 200 mg twice daily or enalapril 10 mg twice daily, with composite cardiovascular death or heart-failure hospitalization as primary outcome [4]. The DAPA-HF trial randomized 4,744 NYHA II-IV heart-failure patients with ejection fraction <=40% to dapagliflozin 10 mg once daily or placebo on top of recommended therapy, testing SGLT2 inhibition in heart failure regardless of type 2 diabetes status [5]. The 2016 ESC guidelines for atrial fibrillation management, developed with EACTS, were published in both EP Europace and European Heart Journal versions [6, 7].
Recent publications
- 2013 ACCF/AHA Guideline for the Management of Heart FailureDOI
- 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failureDOI
- Apixaban versus Warfarin in Patients with Atrial FibrillationDOI
- European Guidelines on cardiovascular disease prevention in clinical practice (version 2012): The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts) * Developed with the special contribution of the European Association for Cardiovascular Prevention Rehabilitation (EACPR)DOI
- Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S)
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESCDOI
- Angiotensin鈥揘eprilysin Inhibition versus Enalapril in Heart FailureDOI
- Dapagliflozin in Patients with Heart Failure and Reduced Ejection FractionDOI
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSDOI
- 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTSDOI
The lab page does not clearly state student acceptance status. Email the professor directly to confirm.
How to apply
Email John J.V. McMurray 6-12 months before your application deadline. Read several recent papers and reference specific work in your message. Use our how to email a Japanese professor guide for the proven email structure.
For applications via MEXT scholarship: see our MEXT 2027 complete guide and university-specific University Recommendation track.
External profiles
- ORCID: https://orcid.org/0000-0002-6317-3975
- OpenAlex: openalex.org
Profile compiled from public sources (Researchmap, OpenAlex, Nagoya University faculty directory). Last refreshed 2026-05. Report incorrect information.